体外診断機器市場：製品別、エンドユーザー別-2025-2030年の世界予測

体外診断機器市場は、2023年に241億8,000万米ドルと評価され、2024年には262億3,000万米ドルに達すると予測され、CAGR 8.58%で成長し、2030年には430億4,000万米ドルになると予測されています。

体外診断（IVD）機器市場には、血液、尿、組織などのサンプルの検査を実施するためにラボで使用される幅広い機器が含まれ、病気の診断、治療のモニタリング、健康状態の予防に役立っています。IVD装置の必要性は、迅速かつ正確な検査結果を提供する能力に起因しており、効果的な患者管理とヘルスケアコストの削減に不可欠です。調査用途には、臨床化学、免疫化学、分子診断、血液学などがあり、最終用途は病院、学術機関、診断センター、研究所など多岐にわたる。主な成長要因としては、慢性疾患の有病率の上昇、高齢者人口の増加、テクノロジーの進歩、個別化医療の需要などが挙げられます。ポイントオブケア検査機器の開発、在宅医療現場での使用拡大、診断向上のための人工知能の統合など、ビジネスチャンスは豊富にあります。こうした機会を捉えるための推奨事項としては、革新的なソリューションの研究開発への投資や、市場拡大のための戦略的パートナーシップの形成などが挙げられます。しかし、市場の成長は、厳しい規制要件、高い開発コスト、競合からの圧力といった課題に直面しており、これらは中小企業の参入を制限し、新製品の市場投入までの時間を長くする可能性があります。技術革新が必要な分野としては、費用対効果が高く、迅速で携帯可能な診断ツールの開発や、精度を高めるための分子診断技術の開発などが挙げられます。市場はダイナミックな競合情勢に特徴付けられ、主要企業は競争上の優位性を獲得するために技術の進歩や新製品の上市に努めています。業界がデジタル化され相互接続されたソリューションに移行するにつれ、診断におけるデータプライバシー、相互運用性、サイバーセキュリティの重視がますます重要になっています。この進化する市場で成功するために、企業は製品の信頼性を高め、検査時間を短縮し、従来の環境から医療や消費者の幅広いニーズに対応するアプリケーションを拡大することに注力すべきです。

市場力学：急速に進化する体外診断機器市場の主要市場インサイトを公開

体外診断機器市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢者人口の増加と慢性疾患および感染症の著しい蔓延
  • 先進地域における全自動およびPOC機器の導入と利用可能性の増加
  • 疾患の適応と診断に関する意識の高まり
• 市場抑制要因
  • 不利な償還オプション
• 市場機会
  • ターゲットを絞った製品開発と商業化
  • 共同研究と製品開発
• 市場の課題
  • 厳しい規制要件

ポーターの5つの力：体外診断機器市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：体外診断機器市場における外部からの影響の把握

外部マクロ環境要因は、体外診断機器市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析体外診断機器市場における競合情勢の把握

体外診断機器市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス体外診断機器市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、体外診断機器市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨体外診断機器市場における成功への道筋を描く

体外診断機器市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化人口の増加と慢性疾患および感染症の蔓延
    • 先進地域での完全自動化機器およびPOC機器の導入と利用可能性の向上
    • 病気の兆候と診断に関する意識の向上
  • 抑制要因
    • 不利な払い戻しオプション
  • 機会
    • ターゲットを絞った製品開発と商品化
    • 共同調査と製品開発
  • 課題
    • 厳格な規制要件
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 体外診断機器市場：製品別

• 臨床微生物学
• 血液学
• 止血
• 免疫化学
• 分子診断
• ポイントオブケア
• 血糖値の自己モニタリング
• 組織診断

第7章 体外診断機器市場：エンドユーザー別

• 学術調査機関
• ホームケア
• 病院および診断研究所

第8章 南北アメリカの体外診断機器市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の体外診断機器市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの体外診断機器市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Accelerate Diagnostics, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Biomerieux SA
• Diasorin S.P.A.
• F. Hoffmann-La Roche Ltd.
• GenomeMe Inc.
• Grifols SA
• Hologic, Inc.
• PerkinElmer Inc.
• Qiagen N.V.
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. IN-VITRO DIAGNOSTICS INSTRUMENT MARKET RESEARCH PROCESS
• FIGURE 2. IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. IN-VITRO DIAGNOSTICS INSTRUMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IN-VITRO DIAGNOSTICS INSTRUMENT MARKET DYNAMICS
• TABLE 7. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY CLINICAL MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HEMOSTASIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY IMMUNOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY POINT-OF-CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY SELF-MONITORING OF BLOOD GLUCOSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY TISSUE DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. CANADA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. CANADA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. MEXICO IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. UNITED STATES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 35. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. ASIA-PACIFIC IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. AUSTRALIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. AUSTRALIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. CHINA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 40. CHINA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. INDIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. INDIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. INDONESIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. INDONESIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. JAPAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. JAPAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. MALAYSIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. MALAYSIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. PHILIPPINES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. PHILIPPINES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. SINGAPORE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. SINGAPORE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. SOUTH KOREA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. SOUTH KOREA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. TAIWAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. TAIWAN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. THAILAND IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. THAILAND IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. VIETNAM IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. VIETNAM IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. EUROPE, MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. DENMARK IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. DENMARK IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. EGYPT IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. EGYPT IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. FINLAND IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. FINLAND IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. FRANCE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. FRANCE IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. GERMANY IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 73. GERMANY IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. ISRAEL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. ISRAEL IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. ITALY IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. ITALY IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. NETHERLANDS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. NETHERLANDS IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. NIGERIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. NIGERIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. NORWAY IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. NORWAY IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. POLAND IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. POLAND IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. QATAR IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. QATAR IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. RUSSIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. RUSSIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. SAUDI ARABIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. SAUDI ARABIA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH AFRICA IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. SPAIN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. SPAIN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. SWEDEN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. SWEDEN IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. SWITZERLAND IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. SWITZERLAND IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. TURKEY IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. TURKEY IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. UNITED ARAB EMIRATES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. UNITED ARAB EMIRATES IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. UNITED KINGDOM IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. UNITED KINGDOM IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. IN-VITRO DIAGNOSTICS INSTRUMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 107. IN-VITRO DIAGNOSTICS INSTRUMENT MARKET, FPNV POSITIONING MATRIX, 2023

The In-Vitro Diagnostics Instrument Market was valued at USD 24.18 billion in 2023, expected to reach USD 26.23 billion in 2024, and is projected to grow at a CAGR of 8.58%, to USD 43.04 billion by 2030.

The In-Vitro Diagnostics (IVD) Instrument market encompasses a wide range of devices used in laboratories to perform tests on samples such as blood, urine, and tissue, aiding in disease diagnosis, treatment monitoring, and health condition prevention. The necessity of IVD instruments stems from their ability to provide quick and accurate test results, crucial for effective patient management and reducing healthcare costs. Applications include clinical chemistry, immunochemistry, molecular diagnostics, and hematology, with end-use scope spanning hospitals, academic institutions, diagnostic centers, and research laboratories. Key growth influencers include the rising prevalence of chronic diseases, increasing geriatric population, advances in technology, and demand for personalized medicine. Opportunities abound in developing point-of-care testing devices, expanding use in home-care settings, and integrating artificial intelligence for improved diagnostics. Recommendations to seize these opportunities include investing in R&D for innovative solutions and forming strategic partnerships to broaden market reach. However, market growth faces challenges such as stringent regulatory requirements, high development costs, and competitive pressure, which can limit smaller players' entry and longer time-to-market for new products. Areas ripe for innovation include developing cost-effective, rapid, and portable diagnostic tools and exploring molecular diagnostic techniques for enhanced precision. The market is characterized by a dynamic and competitive landscape, with key players striving for technological advancements and newer product launches to gain competitive advantages. Emphasis on data privacy, interoperability, and cybersecurity in diagnostics is increasingly crucial as the industry shifts towards digital and interconnected solutions. To thrive in this evolving market, companies should focus on enhancing product reliability, reducing testing times, and expanding applications beyond traditional settings to suit a wider array of medical and consumer needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In-Vitro Diagnostics Instrument Market

The In-Vitro Diagnostics Instrument Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising geriatric population and significant prevalence of chronic and infectious diseases
  • Increasing adoption and availability of fully automated and POC instruments in developed regions
  • Increased awareness about disease indication & diagnostics
• Market Restraints
  • Non-favourable reimbursement options
• Market Opportunities
  • Targeted product development and commercialization
  • Collaborative research and product development
• Market Challenges
  • Stringent regulatory requirements

Porter's Five Forces: A Strategic Tool for Navigating the In-Vitro Diagnostics Instrument Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In-Vitro Diagnostics Instrument Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In-Vitro Diagnostics Instrument Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In-Vitro Diagnostics Instrument Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In-Vitro Diagnostics Instrument Market

A detailed market share analysis in the In-Vitro Diagnostics Instrument Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In-Vitro Diagnostics Instrument Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In-Vitro Diagnostics Instrument Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In-Vitro Diagnostics Instrument Market

A strategic analysis of the In-Vitro Diagnostics Instrument Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In-Vitro Diagnostics Instrument Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux SA, Diasorin S.P.A., F. Hoffmann-La Roche Ltd., GenomeMe Inc., Grifols SA, Hologic, Inc., PerkinElmer Inc., Qiagen N.V., Siemens Healthineers, Sysmex Corporation, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the In-Vitro Diagnostics Instrument Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Clinical Microbiology, Hematology, Hemostasis, Immunochemistry, Molecular Diagnostics, Point-of-Care, Self-Monitoring of Blood Glucose, and Tissue Diagnostics.
• Based on End User, market is studied across Academic & Research Institutes, Homecare, and Hospitals & Diagnostic Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising geriatric population and significant prevalence of chronic and infectious diseases
    • 5.1.1.2. Increasing adoption and availability of fully automated and POC instruments in developed regions
    • 5.1.1.3. Increased awareness about disease indication & diagnostics
  • 5.1.2. Restraints
    • 5.1.2.1. Non-favourable reimbursement options
  • 5.1.3. Opportunities
    • 5.1.3.1. Targeted product development and commercialization
    • 5.1.3.2. Collaborative research and product development
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. In-Vitro Diagnostics Instrument Market, by Product

• 6.1. Introduction
• 6.2. Clinical Microbiology
• 6.3. Hematology
• 6.4. Hemostasis
• 6.5. Immunochemistry
• 6.6. Molecular Diagnostics
• 6.7. Point-of-Care
• 6.8. Self-Monitoring of Blood Glucose
• 6.9. Tissue Diagnostics

7. In-Vitro Diagnostics Instrument Market, by End User

• 7.1. Introduction
• 7.2. Academic & Research Institutes
• 7.3. Homecare
• 7.4. Hospitals & Diagnostic Laboratories

8. Americas In-Vitro Diagnostics Instrument Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific In-Vitro Diagnostics Instrument Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa In-Vitro Diagnostics Instrument Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Accelerate Diagnostics, Inc.
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. Biomerieux SA
• 6. Diasorin S.P.A.
• 7. F. Hoffmann-La Roche Ltd.
• 8. GenomeMe Inc.
• 9. Grifols SA
• 10. Hologic, Inc.
• 11. PerkinElmer Inc.
• 12. Qiagen N.V.
• 13. Siemens Healthineers
• 14. Sysmex Corporation
• 15. Thermo Fisher Scientific, Inc.